This Government Contract opportunity from Department Of Defense was posted on May 27, 2026. The submission period has ended. Browse the details below for market research, or find similar active opportunities.

Top

Pharmaceutical Manufacturing of Milbemycin Oxime

Closed

Federal

Submission Closed06/02/2026, 05:00:00 PM UTC

Contract Overview

Solicitation details, issuing organization, response deadlines, documents, and interested companies for this government contract opportunity.

Active Opportunities Like This One

NAICS: 325412

New

DIBBS

METOPROLOL TARTRATEThe contract pertains to the procurement of Metoprolol Tartrate, identified by the National Stock Number 6505-01-615-1537, with a requested quantity of one unit under purchase request number 7017142424. The solicitation, numbered SPE2DP-26-T-3815, was posted by the Defense Logistics Agency, a branch of the Department of Defense, on June 16, 2026. The deadline for responses to this solicitation is June 22, 2026, indicating a brief window for bid submissions. This contract is categorized as a solicitation from a federal agency, with no specified type of set-aside or NAICS code provided. The place of performance and office location details are unspecified beyond being within the United States. The solicitation is accessible through the Defense Logistics Agency’s bidding system, and it appears focused on securing this specific pharmaceutical item for defense-related use.

Defense Logistics Agency

POSTED

DEADLINE

Wound Infection Prevention & Sepsis Countermeasure Development

Army Medical Resources Acq Activity

POSTED

DEADLINE

6505--Dutasteride CapsulesThe Department of Veterans Affairs National Acquisition Center plans to issue a Request for Proposal (RFP 36E79726R0029) for the procurement of Dutasteride Capsules to serve multiple federal agencies, including the VA, Department of Defense, Bureau of Prisons, Indian Health Service, and Federal Health Care Center. This unrestricted contract aims to secure a reliable supply source for Dutasteride 0.5MG capsules in both 30-count and 90-count bottles, with annual estimated usage of approximately 3,912 and 25,502 bottles respectively. The contract will be awarded to a single responsible offeror who can provide an uninterrupted supply and will have a one-year base period followed by four one-year option periods. Distribution will be managed through the VA and DoD Pharmaceutical Prime Vendor Programs. Offerors must supply the drug under the exact name on the label, with a unique National Drug Code (NDC) exclusive to the offeror. The contractor’s label must be the sole label on the product, with VA labels designed to adhere securely on top without obscuring important information such as barcodes, expiration dates, and lot numbers. Packaging requirements include safety caps that meet specific design criteria with a minimum bottle volume of 120cc and cylindrical shape to accommodate appropriate labeling sizes. The solicitation will be released in a commercial item format in accordance with FAR Part 12 around June 22, 2026, with proposals due by July 7, 2026. Interested parties should monitor SAM.gov for updates and submit offers electronically; efforts to obtain paper copies will not be accommodated. The contract specialist and primary point of contact for this procurement is Richard Mahario.

Nac Pharmaceuticals (36E797)

POSTED

DEADLINE

LEVOFLOXACIN TABLETThe contract pertains to the procurement of Levofloxacin tablets, identified by NSN/Part Number 6505-01-444-6632, with a purchase quantity of one unit under request number 7017178498. The solicitation, designated SPE2DP-26-T-3807, was issued by the Defense Logistics Agency on behalf of the Department of Defense with a posting date of June 15, 2026, and a response deadline set for June 22, 2026. This solicitation is categorized as a federal opportunity without specific set-aside conditions or NAICS code information provided. The contract will be performed within the United States, although exact location details are unspecified. The Defense Logistics Agency is managing the acquisition, and the solicitation details are accessible via a designated DIBBS URL for interested parties.

Defense Logistics Agency

POSTED

DEADLINE

Sole Source Total Parenteral Nutrition (TPN) solutions, including TrophAmine, Plenamine, Nutrilipid, and SMOF Lipid same-day delivery, seven days a weekThis contract involves the sole source procurement of Total Parenteral Nutrition (TPN) solutions, specifically including products such as TrophAmine, Plenamine, Nutrilipid, and SMOF Lipid. The key requirement is for same-day delivery, seven days a week, ensuring continuous availability of these critical nutritional solutions. The solicitation number is HT941026N0069, with the notice posted on June 15, 2026, and a response deadline set for June 30, 2026. The contract falls under the NAICS code 325412, associated with pharmaceutical preparation manufacturing, and is issued by the Defense Health Agency located at Camp Pendleton, California. The place of performance is identified within Washington state, ZIP code 98431, indicating where the deliveries or contract services will be conducted. There is no set-aside designation for this procurement, reflecting an open competitive strategy or a direct sole-source justification. Primary and secondary points of contact are provided for further inquiries, with the primary contact being CHA-ON Gordon. The contract aims to support the Department of Defense’s ongoing medical and nutritional needs for personnel, emphasizing timely and reliable supply chain delivery for essential TPN products.

Defense Health Agency Hcd West

POSTED

2 days ago

DEADLINE

in 14 days

AI Contract Overview

This contract involves the manufacturing of Milbemycin Oxime, a veterinary antiparasitic agent, encompassing the complete process from synthesis and purification to initial packaging. The work must be conducted in compliance with current Good Manufacturing Practices (cGMP) and FDA regulations, ensuring the highest quality standards for pharmaceutical production. The contract is positioned as a subcontract opportunity under the Department of Defense through the Medical Supply Chain Pharm FSA and is identified with NAICS code 325412, which pertains to pharmaceutical manufacturing. The place of performance for this contract is specified as APO, with the ZIP code 09227-0000, indicating a location supporting military or overseas operations. The solicitation was posted on May 27, 2026, with a response deadline of June 2, 2026, providing a limited window for interested parties to submit their proposals. There is no designated small business set-aside, allowing all eligible manufacturers to compete. This contract emphasizes stringent regulatory adherence and is geared toward ensuring a reliable supply of veterinary pharmaceuticals within a defense-related supply chain context.

General Info

Manufacture Milbemycin Oxime under cGMP for DoD vet supply chain, APO location, bids due 6/2/26.

Agency

Department Of Defense → MEDICAL SUPPLY CHAIN PHARM FSA

NAICS

325412 - Pharmaceutical Preparation Manufacturing View NAICS

Place of Performance

APO, AE, 09227-0000, US

Set-Aside

NONE

Documents

(0)

No documents available

AI Contract Breakdown

Uniform Contract Format

No contract breakdown available.

Cannot generate Contract Breakdown because no documents were found from this contract's source.

Timeline

PhaseClosed

PostedMay 27

subcontract

Response DeadlineJun 2

Deadline has passed

Submission Closed

06/02/2026, 05:00:00 PM UTC

Find active opportunities like this

Start your free trial to discover similar active contracts, track opportunities, and build proposals with AI assistance.

Organization & Contact Information

AgencyDepartment Of Defense → MEDICAL SUPPLY CHAIN PHARM FSA

ContactsNo contacts available

OfficeN/A

Organization / Agency

Department Of Defense → MEDICAL SUPPLY CHAIN PHARM FSA

Office AddressN/A

ContactsNo contact information available

Full Description

Manufacture of Milbemycin Oxime, a veterinary antiparasitic agent, including synthesis, purification, and initial packaging under cGMP and FDA compliance.